Close
FINDING CURES TOGETHER<sup>SM</sup>

Cancer Dormancy and Residual Disease

​Program 


Tuesday, June 19

Wednesday, June 20

Thursday, June 21

Tuesday, June 19

Welcome and Opening Keynotes
5-7 p.m.

The cancer dormancy paradigm and how it transformed metastasis research
Julio A. Aguirre-Ghiso, Icahn School of Medicine at Mount Sinai, New York, New York

The grand challenge: How to distinguish normal from dormant breast cancer cells?
Mina Bissell, Lawrence Berkley National Laboratory, Berkeley, California


Welcome Reception

7-9 p.m.​​


Wednesday, June 20

Plenary Session 1: The Role of DTC Heterogeneity in Early Systemic Cancer, Distant Site Adaptation, and Selection​
Session Chairs: Julio A. Aguirre-Ghiso, Icahn School of Medicine at Mount Sinai, New York, New York, and Rachelle Johnson, Vanderbilt University Medical Center, Nashville, Tennessee
8-10:15 a.m.

From early dissemination to metastatic colonization: What happens during dormancy?
Christoph A. Klein, University of Regensburg, Regensburg, Germany

Genomic profiling of minimal residual cancer cells
Nikolas Stoecklein, University of Düsseldorf, Düsseldorf, Germany

Evolution of lethal metastatic cancer at primary and metastatic sites: Can we identify what is important?
G. Steven Bova, University of Tampere, Tampere, Finland

Clonal dynamics during tumor regression, residual disease, and recurrence*
James Alvarez, Duke University School of Medicine, Durham, North Carolina

The earliest precursor cell of melanoma metastasis: Identification and molecular characterization of candidate metastasis founders*
Courtney König, University of Regensburg, Regensburg, Germany

NR2F1 limits dissemination and stem-like features of early cancer mammary epithelial cells*
M. Soledad Sosa, Icahn School of Medicine at Mount Sinai, New York, New York


Break

10:15-10:30 a.m.


Plenary Session 2: Pro-dormancy Niches
Session Chairs: Cyrus M. Ghajar, Fred Hutchinson Cancer Research Center, Seattle, Washington, and M. Soledad Sosa, Icahn School of Medicine at Mount Sinai, New York, New Y​ork
10:30 a.m.-1 p.m.

The perivascular niche protects disseminated tumor cells from therapy
Cyrus M. Ghajar

Elucidating the bone marrow niches of dormant, treatment-resistant leukemic cells and disseminated breast cancer cells
Dorothy A. Sipkins, Duke University, Durham, North Carolina

Stem cell pathways in dormancy and reactivation
Filippo Giancotti, The University of Texas MD Anderson Cancer Center, Houston, Texas

Regulation of tumor dormancy by hypoxia
Rachelle Johnson, Vanderbilt University Medical Center, Nashville, Tennessee

Melanoma dormancy and the aged tumor microenvironment: WNT5A drives disseminated melanoma cell dormancy*
Mitchell E. Fane, Wistar Institute, Philadelphia, Pennsylvania 

Inhibiting metastatic outgrowth of dormant tumor cells using soluble mediators of resolution-promoting macrophages*
Dalit Barkan, University of Haifa, Haifa, Israel

     

Lunch on Own
1-3 p.m.​​​​​​​


Plenary Session 3:
Metastatic Niches
Session Chairs: Rosandra Kaplan, National Cancer Institute, Bethesda, Maryland, and Dalit Barkan, University of Haifa, Haifa, Israel
3-5:30 p.m.

New protagonists of the tumor microenvironment
Ilaria Malanchi, The Francis Crick Institute, London, United Kingdom

Microenvironmental control of bone metastasis in breast cancer
Alana Welm, Huntsman Cancer Institute, Salt Lake City, Utah

Claudin-2 is a mediator of breast and colorectal cancer metastasis
​​Peter Siegel, McGill University, Montreal, QC, Canada

The role of stromal cell plasticity in the dormant to proliferative switch of disseminated cancer cells
Rosandra Kaplan

NRP2-SEMA3s-PLXNs axis regulates the dormancy state of disseminated tumor cells and metastasis progression in breast and head and neck cancer*
Leire Recalde-Percaz, University of Barcelona, Barcelona, Catalonia, Spain 

Glioma cells with downregulated IGF-IR expression can persist in the brain in a dormant state*
Pnina Brodt, Research Institute of the McGill University Health Center, Montreal, QC, Canada

​​
Poster Session A / Reception

5:30-7:30​ p.m.


Thursday, June 21

​Keynote Presentation
8-9 a.m.

Mechanisms of HIV reservoir maintenance
Daniel Douek, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland

Plenary Session 4: Reservoirs of Disease: Parallels between Cancer, HIV, and Tuberculosis
Session Chairs: Daniel Douek, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, and Darren Carpizo, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
9-10:30 a.m.

Title to be announced​
Rafick-Pierre Sékaly, Case Western Reserve University, Cleveland, Ohio

Targeting the one in a million: Detection and elimination of the HIV latent reservoir
Ya-Chi Ho, Yale School of Medicine, New Haven, Connecticut 

In vivo gene editing of latent herpes simplex virus and HIV: Lessons from direct attacks on viral reservoirs
Keith Jerome, Fred Hutchinson Cancer Research Center, Seattle, Washington


Break

10:30-11 a.m.


Plenary Session 5:
Protective Niches for Stem Cells in Adult Tissues
Session Chairs: Dorothy A. Sipkins, Duke University, Durham, North Carolina, and Paloma Bragado, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
11 a.m.-12:45 p.m.

Dormancy in normal and malignant stem cells
Andreas Trumpp, Heidelberg Institute for Stem Cell Technology and Regenerative Medicine, Heidelberg, Germany

Pathways regulating tumor dormancy by the hematopoietic stem cell niche
Russell Taichman, University of Michigan, Ann Arbor, Michigan

scRNAseq approaches to define gene signatures that may control dormancy in myeloma
Peter Croucher, Garvan Institute of Medical Research, Sydney, Australia

​Visualizing tumor dormancy in mouse models of cancer*
Joshua C. Snyder, Duke University School of Medicine, Durham, North Carolina


Poster Session B / Lunch
12:45-3:30 p.m.​


Plenary Session 6: Technologies to Image and Profile Disseminated Tumor Cells
Session Chairs: Jason Bielas, Fred Hutchinson Cancer Research Center, Seattle, Washington, and Courtney König, University of Regensburg, Regensburg, Germany
3:30-5:30 p.m.         

High resolution multiphoton imaging of the mechanism of how breast and pancreatic adenocarcinoma initiate and sustain systemic dissemination
John Condeelis, Albert Einstein College of Medicine, Bronx, New York

Visualizing immune cell fate decisions, blood cancers and tissue remodeling with long-term in vitro and in vivo microscopy
Edwin D. Hawkins, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

Next generation sequencing to detect and quantify rare cell populations at the single cell level
​Jason Bielas, Fred Hutchinson Cancer Research Center, Seattle, Washington 

Isolation and analysis of bone marrow disseminated tumor cells from patients with localized prostate cancer*
Frank Cackowski, University of Michigan, Ann Arbor, Michigan

Single-cell transcriptomic profiling identifies a dormancy signature in a novel mouse model of pancreatic cancer dormancy*
Crissy Dudgeon, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey


Evening Off
5:30 p.m.​​​


Friday, June 22
 
​Plenary Session 7Dormancy and Immune Evasion
Session Chairs: Daniela F. Quail, McGill University Goodman Cancer Center, Montreal, QC, Canada, and Frank Cackowski, University of Michigan, Ann Arbor, Michigan
8-10:15 a.m.

​Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells
Mikala Egeblad, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

The MYC oncogene regulates the immune response influencing tumor initiation, progression and dormancy
Dean W. Felsher, Stanford University, Stanford, Stanford, California

Targeting macrophages in the brain tumor microenvironment
Daniela F. Quail

NK cells govern breast cancer latency in the liver*
Ana Luisa Correia, University of Basel/University Hospital Basel, Basel, Switzerland

Estrogen promotes immune evasion in the liver to enhance metastatic expansion*
Simon Milette, McGill University, Montreal, QC, Canada 

The role of the tumor microenvironment in breast cancer dormancy*
Andrea Walens, Duke University, Durham, North Carolina


Break
10-10:30 a.m.


Plenary Session 8:
Translating Dormancy to the Clinic
Session Chairs: Christoph A. Klein, University of Regensburg, Regensburg, Germany, and Simon Milette, McGill University, Montreal, QC, Canada
10:30 a.m.-12:30 p.m.       

Tumor dormancy in the clinic: The curious case of late relapse
Kathy D. Miller, Indiana University School of Medicine, Indianapolis, Indiana

Clinical potential of targeting leukemic stem cells to reduce the burden of minimal residual disease
Ravi Bhatia, University of Alabama, Birmingham, Alabama

Development of a clinical trial to induce therapeutic dormancy in prostate cancer
​​William Oh, Icahn School of Medicine at Mount Sinai, New York, New York

Investigating Dec2 as a biomarker of human dormant metastatic tumor cells in colorectal cancer*
Darren Carpizo, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 

Selective inhibition of the stress kinase PERK blocks HER2-driven tumorigenesis and suppresses metastasis by targeting quiescent disseminated tumor cells*
Veronica Calvo, Icahn School of Medicine at Mount Sinai, New York, New York 


Closing Remarks
12:30 p.m.


*Short talks from proffered abstracts 


Top of page